공지사항

Multiple Myeloma and csx transportation acute myeloid leukemia csx transportation acute lymphocytic leukemia

According to the lawsuit, Peter worked for Csx Transportation Mds the Long Island Railroad Company (LIRR) for 29 years and during that time, he was exposed to numerous hazardous chemicals. These chemicals and substances included creosote and diesel fumes.

Multiple myeloma is a disease that affects the plasma cells that produce antibodies to fight disease and infections. These cancerous cells multiply in bones, and form tumors called plasmacytomas.

Symptoms

The cancer affects plasma cells, which make antibodies that help the body fight infections and germs. The symptoms of Multiple Myeloma include back pain and the ribs. It also causes brittle bones that break easily weakening, fatigue and loss of appetite and kidney issues.

Myeloma usually isn't symptomatic in its early stages. In fact, a doctor may only discover it when a routine test for a different disease reveals more protein in the urine or blood than is normal. This is known as smoldering myeloma. Myeloma can cause damage to organs, such as the kidneys, lung or nervous system in its later stages. It can cause balance and vision problems.

Your outlook is based on the stage of myeloma that you have, other health issues you have and the age you're at when diagnosed. Your outlook is also influenced by the extent to which plasma cells are producing tumors and creating complications and also the genetic factors that impact the likelihood of developing myeloma.

People with a chromosomal anomaly known as deletion 17p, or duplication 18q, have a worse outlook than those who do not have these abnormalities. Kidney function is also important when your kidneys don't function similarly, you are less likely to succeed. The level of creatinine present in your blood is a good indicator of how well your kidneys are functioning.

Diagnosis

Multiple myeloma can be diagnosed when a person's blood or urine is tested for another illness and an excess amount of protein is identified. Myeloma symptoms include bone pain; weakness of the bones, such as the ribs and back kidney issues and a fever with no known reason; bleeding or bruising; bleeding frequently; and difficulty breathing.

The disease is more prevalent in people who are older and is often seen in men over 60. People with a first-degree family member with myeloma face an average of 2 to 3 times greater risk of being diagnosed over other people. This includes siblings, parents and children.

There are a variety of risk factors for myeloma. They include a previous diagnosis of solitary plasmacytoma of the bone or extramedullary plasmacytoma of soft tissue (such as the throat or lung). Myeloma is more prevalent in people who have been exposed to radiation or chemicals such as asbestos, pesticides and benzene. Myeloma can also be more common in those with a high level of monoclonal-gammopathy with unknown significance (MGUS).

Two toxicologists and an epidemiologist served as the plaintiffs' expert witness. Toxicology, a branch of science, investigates how chemicals can be harmful and how exposure could cause disease. Epidemiology studies the causes and consequences, such as those of myeloma. This is done through the study of medical records and data.

Treatment

The treatment of myeloma is centered on chemotherapy and radiation. There are currently a variety of chemotherapy drugs available. There is also a new class of drugs called monoclonal antibodies, which can kill myeloma cells. Daratumumab as well as elotuzumab and a few other drugs are among them. The combination of these drugs can improve outcomes. Other treatments include immunotherapies, transplants and cell-based vaccines.

While myeloma can affect people of any age, certain factors increase the likelihood of developing the disease. People who are older than 45 are at higher risk and those who have a family history of multiple myeloma. People who have been exposed to chemicals or radiation are also at higher risk. This includes people who have been exposed to X-rays and those who were employed in industries that used asbestos, benzene and herbicides such as Agent Orange.

Ronald Harris died in 2013 from multiple myeloma. His estate filed a lawsuit against csx transportation mds Transportation, claiming that his railroad work contributed to his cancer. The trial court allowed an evidentiary hearing, and heard the testimony of three plaintiffs' experts in science such as Dr. Goldstein, Dr. Infante and Dr. Durie. They relied on reliable methods to demonstrate that csx transportation stomach cancer diesel exhaust fumes exposure caused Harris myeloma. The testimony of the expert witness was based on studies of human subjects and animal studies, the chemical composition and closely related pyrogenic material from diesel exhaust, and experiments with B lymphocytes.

Prognosis

Multiple myeloma affects the plasma cells. These cells are vital to the immune system as they help the body fight diseases and infections. In people with myeloma, plasma cells start to multiply out of control and crowd out normal bone marrow. This can lead to other health issues such as low blood counts and damage to the bones.

A variety of risk factors increase the chance of developing multiple myeloma. Family history, age and exposure to radiation as well as certain chemicals are all risk factors. A first-degree relative who has multiple myeloma is twice as likely to contract it themselves. Myeloma is also more prevalent in black people than in white people.

Ronald Harris was a railroad trainman for csx transportation leukemia Transportation. He worked there for 29 years. He was exposed to diesel exhaust from locomotives on an everyday basis. While working, Harris was diagnosed with multiple myeloma. a form of cancer which attacks plasma cells inside the bone marrow. Harris filed a lawsuit against csx transportation throat cancer under the Federal Employers' Liability Act, and Locomotive Inspector Act. Unfortunately, Harris died while the case was pending. His widow, Deborah Kay Harris, became the plaintiff.

Petitioner retained Dr. Peter Shields and Dr. Laura Green as expert witnesses for the trial. In the two-day hearing, both experts gave evidence about their background and the method that they used to render their opinions. Both experts rely on the Bradford Hill methodology.